Exforge® (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact

Krzesinski, Jean-Marie; Cohen, Eric P.
January 2009
Core Evidence;2009, Vol. 4 Issue 1, p1
Academic Journal
Introduction: Hypertension is an important risk factor for cardiovascular disease and its management requires improvement. New treatment strategies are needed. Aims: This review analyses one of these strategies, which is the development of effective and safe combination therapy. Indeed, at least two antihypertensive agents are often needed to achieve blood pressure control. Exforge® (Novartis) is a new drug combination of the calcium channel blocker, amlodipine, and the angiotensin II receptor blocker, valsartan. Evidence review: The amlodipine/valsartan combination is an association of two well-known antihypertensive products with specific targets in cardiovascular protection, namely calcium channel blockade and antagonism of the renin-angiotensin-aldosterone system. This kind of association, with neutral metabolic properties and significant antihypertensive efficacy, could be a useful new antihypertensive product. Currently available data have shown that this new combination is well-tolerated and effective even in severe hypertension. Clinical value: Clinical trials are ongoing for further assessment of the efficacy, compliance, and safety of this combination and its congeners. No data exist to prove that the amlodipine/valsartan combination is better than other antihypertensive strategies for cardiovascular or renal protection, but some trials with other combination therapies show such potential advantage.


Related Articles

  • Lasofoxifene: Evidence of its therapeutic value in osteoporosis. Gennari, Luigi; Merlotti, Daniela; De Paola, Vincenzo; Nuti, Ranuccio // Core Evidence;2009, Vol. 4 Issue 1, p113 

    Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. It is a common disorder in elderly subjects and represents a major public health problem, affecting up to 40% postmenopausal women and 15% of men. Among the several...

  • Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Thornton, Katherine A. // Core Evidence;2009, Vol. 4 Issue 1, p191 

    Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the...

  • Systematic Review: Acupuncture vs Standard Pharmacological Therapy for Migraine Prevention. Zhang, Niushen; Houle, Tim; Hindiyeh, Nada; Aurora, Sheena K. // Headache: The Journal of Head & Face Pain;Feb2020, Vol. 60 Issue 2, p309 

    Background: Standard pharmacological treatment of migraine has many shortcomings. Acupuncture is becoming a more widely used therapy for the prevention and treatment of migraine, but its effectiveness is still in question when compared to the pharmacological treatments even though very few of...

  • Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Deibert, Peter; Xander, Carola; Blum, Hubert E.; Becker, Gerhild // Core Evidence;2009, Vol. 4 Issue 1, p247 

    Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. A new...

  • Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Lieberman, Daniel Z.; Massey, Suena H. // Core Evidence;2009, Vol. 4 Issue 1, p67 

    Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medications in this class available in the United States. Aims: The objective of...

  • Luliconazole for the treatment of fungal infections: an evidence-based review. Khanna, Deepshikha; Bharti, Subhash // Core Evidence;2014, Vol. 9, p113 

    Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this...

  • Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy. Angeloni, Emiliano // Core Evidence;Apr2016, Vol. 11, p1 

    Background: Azilsartan (AZI) is a relatively new angiotensin receptor blocker available for the treatment of any stage of hypertension, which was eventually given in combination with chlorthalidone (CLT). Objective: To review pharmacology and clinical role of AZI monotherapy and AZI/CLT or...

  • Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Krulig, Eliana; Gordon, Kenneth B. // Core Evidence;2010, Vol. 5 Issue 1, p11 

    Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated...

  • Zinc supplementation improves glycemic control for diabetes prevention and management: a systematic review and meta-analysis of randomized controlled trials. Wang, Xinhui; Wu, Wenhui; Zheng, Wanru; Fang, Xuexian; Chen, Liyun; Rink, Lothar; Min, Junxia; Wang, Fudi // American Journal of Clinical Nutrition;Jul2019, Vol. 110 Issue 1, p76 

    Background Although many studies have shown that low zinc status is associated with diabetes, the putative effects of zinc supplementation on glycemic control are inconclusive. Objectives The aim of this meta-analysis of randomized controlled trials was to assess the effects of zinc...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics